Engineering Universal Immunity with Dr. Jacob Glanville, Founder & CEO of Centivax
About the Event
Join MCBcDNA for an evening with Dr. Jacob Glanville, computational immunologist and Founder & CEO of Centivax, for a deep dive into universal vaccines, broad-spectrum antivenom, and the future of immunoengineering.
Dr. Glanville will discuss how Centivax is developing universal influenza vaccines, now through extensive preclinical testing and scheduled for human trials in 2026, and how the company is working towards a universal snake antivenom capable of neutralizing venom toxins from all snake species worldwide. He’ll also share insights from his path from Berkeley MCB undergrad to biotech founder, blending scientific innovation with real-world execution.
The evening will include a presentation, audience Q&A, and time for networking.
Light refreshments and snacks will be provided. Exact location will be sent out closer to the event.
About the Speaker
Jacob Glanville is a serial entrepreneur and computational immuno-engineer. He earned his B.A. in Molecular & Cell Biology from UC Berkeley and his Ph.D. in Computational & Systems Immunology from Stanford University. He founded Distributed Bio in 2012, built it into a profitable antibody engineering company without outside investment, and led it through its $104M acquisition by Charles River Laboratories in 2020. Following the acquisition, he founded Centivax, where he now serves as Founder & CEO, leading programs in universal vaccines, broad-spectrum antivenom, anti-infectives, and immune therapeutics.
Dr. Glanville has developed several foundational technologies in computational and systems immunology, including high-throughput repertoire sequencing, repertoire decoding algorithms, single-cell TCR sequencing, and computationally guided antibody library engineering. He is the inventor of the Centivax universal vaccine platform, the SuperHuman antibody library, and the Tumbler evolution technology, and has served on scientific advisory boards at Stanford and USF. His work spans immunoengineering, vaccine design, antibody discovery, and translating computational biology into real-world countermeasures.